52w high/low | ₹227.9 / ₹83.1 |
P/E ratio | -10.99 |
Dividend | 0 |
ROE | 16.72 |
ROCE | -13.56 |
Face value | 10 |
Book value | ₹-60.36Cr |
Market capital | ₹239.11Cr |
What is shareholding pattern? Who are shareholders?
What is a cash flow statement?
What is a balance sheet?
What is a profit and loss statement?
What are dividends?
What are bonuses?
Krebs Biochemicals & Industries Ltd[KBIL](Formerly Krebs Biochemicals Ltd), promoted by R T Ravi in 1991 is engaged in the manufacture of Active Pharmaceutical Ingredients(API) through Fermentation process, one among very few in the world to do the same. KBIL which commenced commercial operations in the year 1994 with an installed capacity of 60 TPA has now grown to 150 TPA. KBL went to public with an IPO in 1994. KBIL since inception, has adopted global agenda for its growth by focusing on its specific area of expetise 'Fermentation Technology'. During 2001-02, the company has successfully launched Vitamin C(I P Grade) through Fermentation Process. The company has also received ISO 9002 Certification for Unit I at Nellore from Yarsley International Certifications Services accredited by United Kingdom Accreditation Services. The company is now producing and marketing Lovastatin,Simvastatin and Vitamin-C. The company is now in the process of installing a co-generation power plant at Unit-II.